Category Archives: AZBio News

Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to Scientific Advisory Board

Posted on by

Aqualung Therapeutics, an early-stage biotech company developing an anti-inflammatory therapeutic platform for patients with serious unchecked inflammatory disease, has published proof of concept studies in EBio Medicine suggesting eNAMPT as a potential biomarker for the severity of invasive Prostate Cancer (PCa), and eNAMPT- neutralization as an effective therapeutic approach to limit PCa invasion and progression. Based on these findings, Aqualung has added Edwin M. Posadas MD, FACP to the Scientific Advisory Board.
Continue reading→

BIO Leads Group Challenging Administration’s “Most Favored Nation” Rule

Posted on by

On December 4, 2020, the Biotechnology Innovation Organization (BIO), the California Life Sciences Association (CLSA), and BIOCOM California today filed a challenge against the Department of Health and Human Services’ (HHS) attempt, during the final days of the Trump Administration, to implement for the first time ever a “Most Favored Nation” reimbursement policy for certain drugs administered by Medicare Part B providers – drastically altering this system in ways that will harm their ability to serve America’s most vulnerable senior citizens.Continue reading→

C-Path Quantitative Medicine Program Awarded FDA Contract to Develop Tools for Neuroscience Diseases

Posted on by

TUCSON, Ariz., December 2, 2020 — The Critical Path Institute (C-Path) today announced it has been awarded a U.S. Food and Drug Administration (FDA) contract in support of the development of open-source tools to improve the efficiency of trial design for three neuroscience diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD) and Duchenne muscular dystrophy (DMD). C-Path’s Quantitative Medicine (QuantMed) Program will carry out the project through its work in collaboration with its three C-Path Public-Private Partnerships: the Critical Path for Alzheimer’s Disease (CPAD), the Critical Path for Parkinson’s (CPP) and the Duchenne Regulatory Science Consortium (D-RSC).Continue reading→

AquaVitas, LLC Announces Contract from U.S. Government and Health and Human Services for Nationwide Testing of Wastewater for SARS-CoV-2

Posted on by

Award will fund a collaborative effort between AquaVitas, LLC, the Centers for Disease Control and Prevention and Health and Human Services to identify best practices for wastewater SARS- CoV-2 assessment and subsequent data analytics across the U.S.

Phase 1 award will fund assessment of wastewater at up to 100 treatment plants (representing ~10% of the U.S. population).

Optional Phase 2 award will scale to fund assessment of wastewater at up to 340 treatment plants (representing ~30% of the U.S. population in at least 42 states).Continue reading→